Iovance Biotherapeutics: High-Risk, High-Reward Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy IOVA?
Source: Fool
- Significant Revenue Growth: Iovance Biotherapeutics reported a revenue of $263.5 million for fiscal year 2025, reflecting a 60.6% year-over-year increase, indicating initial success for its cancer treatment drug Amtagvi and boosting investor confidence in the company's future.
- Market Expansion Plans: The company is actively seeking approvals for Amtagvi in the EU, UK, and Australia, having already secured approval in Canada, which will help expand its market share globally and enhance long-term profitability.
- FDA Fast Track Designation: Amtagvi has received Fast Track Designation from the U.S. FDA for treating non-small cell lung cancer, which will expedite the drug's development process and address unmet medical needs, further enhancing the company's competitiveness in the biopharmaceutical sector.
- Manufacturing Complexity Challenges: Despite Amtagvi's promising market outlook, its complex manufacturing and administration processes pose profitability challenges for Iovance, as the need for personalized preparation and patient cell collection increases operational costs, potentially impacting future financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 5.410
Low
1.50
Averages
9.50
High
17.00
Current: 5.410
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iovance Biotherapeutics Stock Rises Amid High Short Interest
- Short Interest Pressure: Iovance Biotherapeutics has a high short interest of 39.6%, which, against a market cap of $1.66 billion, indicates market caution regarding its future performance and could lead to increased stock volatility.
- Positive Clinical Trial Data: The company reported a 50% objective response rate in its TIL cell therapy clinical trial for advanced soft-tissue sarcomas, suggesting potential for new market opportunities and enhancing investor confidence in its product pipeline.
- Strong Stock Performance: The stock is trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, reflecting robust upward momentum over the past year, although the RSI at 83.41 indicates it may be overbought and due for a pullback.
- Optimistic Analyst Ratings: Iovance's stock carries a Buy rating with an average price target of $11.23, and recent upward adjustments in analysts' targets reflect growing confidence in its future growth, further supporting the upward trend in its stock price.
See More
Iovance Biotherapeutics: High-Risk, High-Reward Potential
- Significant Revenue Growth: Iovance Biotherapeutics reported a revenue of $263.5 million for fiscal year 2025, reflecting a 60.6% year-over-year increase, indicating initial success for its cancer treatment drug Amtagvi and boosting investor confidence in the company's future.
- Market Expansion Plans: The company is actively seeking approvals for Amtagvi in the EU, UK, and Australia, having already secured approval in Canada, which will help expand its market share globally and enhance long-term profitability.
- FDA Fast Track Designation: Amtagvi has received Fast Track Designation from the U.S. FDA for treating non-small cell lung cancer, which will expedite the drug's development process and address unmet medical needs, further enhancing the company's competitiveness in the biopharmaceutical sector.
- Manufacturing Complexity Challenges: Despite Amtagvi's promising market outlook, its complex manufacturing and administration processes pose profitability challenges for Iovance, as the need for personalized preparation and patient cell collection increases operational costs, potentially impacting future financial performance.
See More
Iovance Biotherapeutics Faces Challenges and Opportunities
- Significant Product Progress: Iovance's Amtagvi generated $263.5 million in revenue for fiscal year 2025, reflecting a 60.6% year-over-year increase, indicating strong market demand and commercial potential, despite poor stock performance.
- Market Expansion Plans: The company is actively seeking approvals for Amtagvi in the EU, UK, and Australia, having already secured approval in Canada, and successful entry into these new markets could significantly boost revenue and market share.
- Clinical Trial Advancements: Amtagvi has received Fast Track Designation from the FDA for non-small cell lung cancer treatment, with several clinical studies underway, and successful outcomes could further solidify its position in cancer treatment.
- Manufacturing Complexity Challenges: The complex production and administration process for Amtagvi, which takes 34 days and requires specialized centers for infusion, poses significant challenges that may impact Iovance's profitability and increase investment risks.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives on these companies.
- Market Dynamics Overview: While specific stocks are not detailed, changes in analyst ratings typically influence investor decisions and may lead to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying U stock, analysts' opinions may provide crucial market insights, aiding them in making more informed investment choices.
- Source of Rating Changes: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, ensuring investors have access to comprehensive information to support their investment strategies.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Iovance Biotherapeutics Stock Rises Amid High Short Interest
- Short Interest Pressure: Iovance Biotherapeutics has a high short interest of 39.6%, which, against a market cap of $1.66 billion, indicates market caution regarding its future performance and could lead to increased stock volatility.
- Positive Clinical Trial Data: The company reported a 50% objective response rate in its TIL cell therapy clinical trial for advanced soft-tissue sarcomas, suggesting potential for new market opportunities and enhancing investor confidence in its product pipeline.
- Strong Stock Performance: The stock is trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, reflecting robust upward momentum over the past year, although the RSI at 83.41 indicates it may be overbought and due for a pullback.
- Optimistic Analyst Ratings: Iovance's stock carries a Buy rating with an average price target of $11.23, and recent upward adjustments in analysts' targets reflect growing confidence in its future growth, further supporting the upward trend in its stock price.
See More
Iovance Biotherapeutics: High-Risk, High-Reward Potential
- Significant Revenue Growth: Iovance Biotherapeutics reported a revenue of $263.5 million for fiscal year 2025, reflecting a 60.6% year-over-year increase, indicating initial success for its cancer treatment drug Amtagvi and boosting investor confidence in the company's future.
- Market Expansion Plans: The company is actively seeking approvals for Amtagvi in the EU, UK, and Australia, having already secured approval in Canada, which will help expand its market share globally and enhance long-term profitability.
- FDA Fast Track Designation: Amtagvi has received Fast Track Designation from the U.S. FDA for treating non-small cell lung cancer, which will expedite the drug's development process and address unmet medical needs, further enhancing the company's competitiveness in the biopharmaceutical sector.
- Manufacturing Complexity Challenges: Despite Amtagvi's promising market outlook, its complex manufacturing and administration processes pose profitability challenges for Iovance, as the need for personalized preparation and patient cell collection increases operational costs, potentially impacting future financial performance.
See More
Iovance Biotherapeutics Faces Challenges and Opportunities
- Significant Product Progress: Iovance's Amtagvi generated $263.5 million in revenue for fiscal year 2025, reflecting a 60.6% year-over-year increase, indicating strong market demand and commercial potential, despite poor stock performance.
- Market Expansion Plans: The company is actively seeking approvals for Amtagvi in the EU, UK, and Australia, having already secured approval in Canada, and successful entry into these new markets could significantly boost revenue and market share.
- Clinical Trial Advancements: Amtagvi has received Fast Track Designation from the FDA for non-small cell lung cancer treatment, with several clinical studies underway, and successful outcomes could further solidify its position in cancer treatment.
- Manufacturing Complexity Challenges: The complex production and administration process for Amtagvi, which takes 34 days and requires specialized centers for infusion, poses significant challenges that may impact Iovance's profitability and increase investment risks.
See More
ImmunityBio and Iovance Stock Dynamics Analysis
- Stock Performance Comparison: IBRX's stock has fallen over 7% this week, dropping to $9 on Wednesday, while IOVA's stock has gained nearly 11%, reaching $4.26 on the same day, indicating differing market sentiments that could influence investor decisions.
- Sales Revenue Growth: ImmunityBio generated $113 million in revenue from Anktiva in 2025, up approximately 700% year-over-year, while Iovance reported about $87 million in Q4, exceeding estimates of $81.01 million, demonstrating strong market demand for both companies' therapies.
- Analyst Outlook Assessment: Analyst estimates from Koyfin suggest ImmunityBio has price targets ranging from $9 to $23, with an average target of $14.75 implying a 64% upside from current levels, while Iovance's targets range from $2 to $16, averaging $8.8, indicating a potential 107% upside, reflecting differing market expectations for both firms.
- Clinical Trial Progress: ImmunityBio's Quilt 2.005 trial shows that 85% of patients maintained a complete response at six months with Anktiva and BCG combination therapy, while Iovance's trial in new tumor types shows a 50% response rate, indicating positive advancements in expanding market potential for both companies.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives on these companies.
- Market Dynamics Overview: While specific stocks are not detailed, changes in analyst ratings typically influence investor decisions and may lead to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying U stock, analysts' opinions may provide crucial market insights, aiding them in making more informed investment choices.
- Source of Rating Changes: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, ensuring investors have access to comprehensive information to support their investment strategies.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
